NFKB1 and metabolic dysfunction-associated steatohepatitis: In a mouse model of nonalcoholic steatohepatitis, SB treatment was reported to suppress the NF-κB-signalling pathway to alleviate the severity of hepatic inflammation and steatohepatitis [221].